SARC-F自评筛查与脊柱关节炎患者肌力、体能、日常活动、PROs及体成分的关联
本研究为横断面研究,纳入213例脊柱关节炎(SpA)患者,其中65.7%为axSpA、34.3%为PsA,分析SARC-F问卷与肌力、体能、日常活动、患者报告结局(PROs)及DXA体成分的关联。结果显示SARC-F≥4与较差肌力、体能、PROs及体成分相关,但对DXA定义肌少症识别能力有限。
要点
- SARC-F≥4在SpA患者中占24.4%,与疾病活动度、肌力和体能显著相关。
- SARC-F≥4对DXA定义肌少症敏感性低(50%)、特异性中等(76%),阴性预测值高(97%)。
- 高BMI和患者总体评估(PGA)与更高SARC-F评分独立相关。
核心结论
- SARC-F与SpA患者疾病活动度、肌力和体能显著相关,但识别DXA定义肌少症的能力有限。
研究设计与样本
- 横断面研究,纳入213例SpA患者(65.7% axSpA,34.3% PsA),比较SARC-F≥4与<4组,并采用线性回归校正年龄和性别。
主要发现
- 54/213例(24.4%)SARC-F≥4;DXA识别肌少症和肌少性肥胖各4例(7.7%)。
- SARC-F≥4患者年龄更大、女性或肥胖比例更高、病程更长、疾病活动度更高、体能和肌力更低、日常活动更少、体成分更不利。
- 总SARC-F评分与肌力、体能、PROs及DXA体成分持续相关;高BMI和PGA与更高SARC-F评分独立相关。
- SARC-F≥4对DXA定义肌少症的敏感性50%、特异性76%、阴性预测值97%。
关键数值与推荐
- SARC-F评分≥4定义为较高肌少症风险。
- SARC-F≥4对DXA定义肌少症:敏感性50%,特异性76%,阴性预测值97%。
临床怎么用
- SARC-F可用于SpA患者肌少症风险初筛,但阴性预测值高、敏感性低,不能替代DXA等客观评估。
- 对SARC-F≥4的SpA患者应关注疾病活动度、肌力、体能及体成分的进一步评估。
局限性
- 横断面设计无法推断因果;DXA定义肌少症病例数少(各4例);结论需进一步研究验证临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to explore the association of the sarcopenia questionnaire Strength, Assistance with walking, Rise from a chair, Climb stairs, Falls (SARC-F) with muscle strength, physical performance, daily activity, patient-reported outcomes (PROs) and body composition in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). METHODS: In this cross-sectional study, patient and disease characteristics including physical function, performance measures and body composition assessed by dual-energy X-ray absorptiometry (DXA) were analysed. Variables were compared between patients with a SARC-F score ≥4 and <4, higher versus lower sarcopenia risk. Linear regression examined associations, adjusted for age and sex. RESULTS: Overall, 54 of 213 patients with SpA (65.7% axSpA, 34.3% PsA) had a SARC-F score ≥4 (24.4%). DXA identified sarcopenia and sarcopenic obesity in 4 patients each (7.7%). Patients with SARC-F scores ≥4 were older, predominantly female or obese, had longer disease duration, higher disease activity, lower physical performance, decreased muscle strength and daily activity and more unfavourable body composition. Total SARC-F score was consistently associated with muscle strength, physical performance, PROs and DXA components. Higher body mass index and patient global assessment were independently associated with higher SARC-F scores. The SARC-F ≥4 threshold showed moderate specificity (76%) but low sensitivity (50%) for DXA-defined sarcopenia, with a high negative predictive value (97%). CONCLUSIONS: SARC-F was significantly associated with disease activity, muscle strength and physical performance, but showed limited ability to identify DXA-defined sarcopenia. Further research is needed to clarify its clinical utility for risk stratification in rheumatic diseases.
引用
- Kononenko J, Bedei M, Buehring B, et al. Association between SARC-F as a self-report screening tool for sarcopenia and muscle strength, physical performance, daily activity, patient-reported outcomes and body composition in patients with spondyloarthritis. RMD Open. 2026. PMID: 41825928. doi:10.1136/rmdopen-2025-006649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。